The pathogenic role of trisomy 12 in chronic lymphocytic leukemia (CLL) remains unresolved, but recently an upregulated RNA expression level has been observed for chromosome 12 candidate genes. In the current study, the protein expression of chromosome 12 candidate genes was characterized by comparing CLL cases with (n ¼ 58) or without (n ¼ 16) trisomy 12, CD19 þ -B-cells and cell lines (JVM-2, EHEB, JURKAT). Immunoblotting was performed to quantify the levels of AID, APAF-1, ARF3, CCND2, CDK2, CKD4, GLI, MDM-2, p27, Smac/ DIABLO and STAT6 (signal transducer and activator of transcription 6). The cell lines showed distinct expression patterns for CCND2, MDM-2, p27, Smac/DIABLO and STAT6, and displayed higher levels of CDK2 and CDK4 than the CLL cases. JURKAT and the CLL cases expressed uniformly high levels of p27, but low levels of CCND2. AID expression in the CLL cases was weak with slight variations regardless of the subgroup affiliation. The expression of the investigated proteins was independent of the trisomy 12 status as well as of the VH mutation status. The comparison of CD19 þ -B-cells with CLL revealed higher protein levels in CLL for CDK4, p27, Smac/ DIABLO and STAT6. Further studies including protein expression experiments in genetic high-risk subgroups of CLL have to elucidate whether these proteins qualify as candidates for targeted CLL therapies.
Introduction
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and is characterized by typical genomic aberrations, trisomy 12 being among the most frequent ones. 1, 2 In several studies, the presence of trisomy 12 has been shown to be associated with a more aggressive clinical course. 1, [3] [4] [5] The role of genes potentially involved in the pathogenesis of CLL with trisomy 12 is not established. While the critical region of most aberrations in CLL could be narrowed down to a set of candidate genes, this has been difficult in the case of trisomy 12. Earlier studies indicated that the bands 12q13-q15 comprise the minimally gained region. 3, [6] [7] [8] Recent RNA expression analyses showed an overexpression of genes located to chromosome 12 in CLL cases with trisomy 12 as compared to cases without this aberration. 9, 10 The aim of the current study was to characterize the protein expression patterns of chromosome 12 candidate genes with oncogenic potential or functional relevance in apoptosis, cell cycle, signal transduction or somatic hypermutation (for details see Table 1 ) when comparing CLL cases with or without trisomy 12, CD19 þ -Bcells from healthy donors and lymphoma cell lines (JVM-2, EHEB and JURKAT).
Materials and methods

Sample characterization
CD19 þ -B-cells were isolated from buffy coats obtained from healthy donors using anti-CD19 magnetic microbeads (Miltenyibiotech, Bergisch Gladbach, Germany) according to the manufacturer's instructions. B-cell purity was 497% as assessed by FACS analysis.
Tumor samples were prepared by Ficoll density-gradient centrifugation from the blood of patients with CLL and molecular cytogenetic analysis as well as VH sequencing were performed as described previously.
2,11 CLL cases showing either a trisomy 12 (n ¼ 58) or a normal karyotype (n ¼ 16) were selected. In addition to trisomy 12, two cases had a 17p deletion, one an 11q deletion and 16 cases a 13q deletion. For the trisomy 12 group, the tumor purity of the sample was defined by the percentage of cells with trisomy 12 as detected by FISH. The criteria for the selection of cases with a normal karyotype by FISH were high lymphocyte counts in combination with a high percentage of CD5 þ and CD19 þ cells as measured by FACS. According to these criteria, the median content of clonal cells was 80% (range: 70-88%) in the trisomy 12 cohort and 88% (range: 44-98%) in the group with a normal karyotype. An unmutated VH status was observed in 32 of 45 cases in the trisomy 12 group and in 11 of 16 cases in the group with a normal karyotype.
Clinical data were available for 32 patients. Treatment-free survival (TFS) after a median follow-up of 59.7 months was 58.3 months in the trisomy 12 group (n ¼ 17) vs 60.0 months in cases with a normal karyotype (n ¼ 15; P-value 0.57). Patients with unmutated VH status (n ¼ 20) had a significantly shorter TFS with 31.1 months compared to patients with mutated VH genes (n ¼ 12; TFS of 86.4 months; P-value 0.012).
Cell lines
The human lymphoma cell lines EHEB (Epstein-Barr virus (EBV)-transformed CLL), JVM-2 (EBV-transformed B-PLL/leukemic mantle cell lymphoma) and JURKAT (non-EBV-transformed T-ALL) were purchased from DSMZ (Braunschweig, Germany) and cultured in RPMI 1640 (Seromed, Berlin, Germany) supplemented with 10% fetal calf serum (Serva, Heidelberg, Germany). To allow for a comparison of different blots, lysates of the cell line EHEB were loaded on all gels as an internal standard. To avoid expression differences of cell cycle proteins in the cell lines, all cells used for the blots shown in Figure 1 were harvested at a single point of time. To gain more information about expression differences in dependence of the time point of harvest, the JVM cells already used for the experiments shown in Figure 1 but freshly harvested EHEB cells were used for the blots shown in Figure 2 .
Immunoblot analyses
A total of 1-10 Â 10 7 cells were lysed in 0.5-1 ml lysis buffer (10 mM Tris base; 5 mM EDTA; 130 mM NaCl; 1% Triton X-100; The protein selection was based on the gene locus and involvement in apoptosis, cell cycle, signal transduction, somatic hypermutation or tumorigenic potential. Emphasis was put on bands 12q13-q15. (h) Low but detectable expression and subtle differences in expression levels of AID, which were independent of the VH mutation status in the CLL samples.
Protein Expression in CLL with trisomy 12
D Winkler et al pH 7.4) containing protease inhibitors (Roche, Basel, Switzerland) and the lysate was cleared by centrifugation. NuPage Gel system (Invitrogen, Karlsruhe, Germany) was used for electrophoresis. After protein transfer to Immobilon-P polyvinylidene difluoride membranes (Millipore, Bedford, USA), immunoblotting was performed using antibodies detecting ARF3, APAF-1, CCND2, CDK2, Smac/DIABLO, STAT6 (signal transducer and activator of transcription 6) (BD Biosciences, Palo Alto, USA), CDK4, MDM-2 (Oncogene, San Diego, USA), GLI, p27 (Santa Cruz Biotechnology, Heidelberg, Germany) and AID (Cell Signaling Technology Inc., Beverly, USA) (see Table 1 ). Actin blots were performed to control for protein content.
Results and discussion
Specific expression patterns of the investigated proteins were identified when comparing CLL cases and the cell lines. The most striking differences among the cell lines were found for CCND2, CDK4, MDM-2, p27, Smac/DIABLO and STAT6 (Figure 1 ). The analysis of MDM-2 ( Figure 1a ) revealed a highly specific pattern for each cell line clearly differing from CLL cases with a lower expression of the p57 band in JURKAT as compared to JVM-2 and EHEB. EHEB had the highest expression of the p57 band of the three cell lines, which all showed at least three MDM-2 bands (p90, p76, p57). The expression of STAT6 (Figure 1b) was low in JURKAT, while EHEB and JVM-2 as well as the CLL samples showed strong signals. The expression of p27 ( Figure 1c ) was higher in JURKAT as compared to EHEB and JVM-2, but similar when comparing JURKAT and the CLL samples. In contrast, CCND2 (Figure 1d ) was not expressed by JURKAT and the CLL samples, but clearly detectable in EHEB and JVM-2, possibly influenced by EBV transformation of EHEB and JVM-2. 12 Interestingly, the expression levels of p27 and CCND2 varied in EHEB but not in JVM-2 between the two series of experiments shown in Figures 1 and 2 . As we used the same JVM-2 samples but two different EHEB samples for the experiments shown in the two figures, this finding clearly demonstrates that the expression of cell cycle proteins in continuous cell lines can vary over time and may be influenced by the time point of their harvest. CDK4 expression was lower in CLL samples when compared to the three cell lines (Figure 1e ). Smac/DIABLO (Figure 1f ) displayed a double band in JURKAT and JVM-2, possibly representing different splice variants. 13 The expression of ARF-3 (Figures 1g and 2d) , APAF-1 ( Figure 2g ) and GLI was as strong in the patient samples as in the cell lines and no difference in expression was seen neither among the CLL cases nor among the cell lines. Overall, the protein expression pattern of the two B-lineage cell lines EHEB and JVM-2 seems to differ from that of CLL cases, especially with regard to cell cycle proteins. Notably, neither cell line, although reportedly established from CLL patients, exhibits typical CLL characteristics, for example, absence of known cytogenetic abnormalities of CLL, including trisomy 12.
14 In fact, JVM-2 carries the t(11;14) associated with mantle cell lymphoma. 15 Therefore, both cell lines may serve as positive controls or internal expression standards, but may be of limited usefulness as model systems for CLL. Especially, the variation of cell cycle protein expression shown in EHEB in this study renders subject to caveat data on cell cycle progression in continuous cell lines.
Several variants of MDM-2 protein have been described, 16 and the proteins p57, p59, p67 and p90 were overexpressed in different combinations in 64% of CLL cases when compared to normal volunteers. 17 MDM-2 protein expression did not distinguish the genetic CLL subgroups in the present analysis, but in all CLL samples coexpression of p90 and p57 was observed (Figure 1a) . If this phenomenon is restricted to CLL, cases with trisomy 12 and cases with a normal karyotype remains to be defined.
STAT6 has been shown to be frequently activated via phosphorylation and translocated to the nucleus in Hodgkin's lymphoma. 18 In contrast, no constitutive nuclear translocation has been found in CLL cells. 19 STAT6 was strongly expressed in all CLL cases as well as in EHEB and JVM-2 without significant Protein (Figure 1b) , whereas no expression was detected in CD19 þ -B-cells (Figure 2a) .
A protein that antagonizes the proliferative effect of CDKcyclin complexes, p27, was highly expressed in all CLL cases comparable with the expression level in JURKAT cells (Figure 1c) . A strong p27 protein expression in CLL has also been reported in other studies 20, 21 and high levels of p27 have been shown to be associated with a poor prognosis in CLL. 21 The current study confirms a strong expression of p27 in CLL (Figure 1c) , but all genetic subgroups investigated showed similar levels of p27. In addition, no expression of p27 was found in CD19 þ -B-cells (Figure 2b) pointing to a subgroupindependent involvement of p27 in the pathogenesis of CLL. The overexpression of CCND2 mRNA has been described in CLL as compared to normal resting B-lymphocytes, 22 and an upregulation of the CCND2 protein in CLL cells has been reported upon stimulation with CpG oligonucleotides and interleukin-2. 20 In contrast, the current study revealed generally low expression levels of CCND2 as well as of CDK2 and CDK4 in CLL irrespective of the trisomy 12 status or the VH status when compared to EHEB and JVM (Figure 1d and e) . Remarkably, the expression of CDK4 in CLL was still higher than in CD19 þ -Bcells, where no expression of CDK4 was detected (Figure 2d ). No expression differences between CD19 þ -B-cells and CLL were seen for CCND2 and CDK2 (Figure 2c and e). These results are concordant with a model in which cell cycle stimulation plays a minor role as compared to the inhibition of apoptosis in the accumulation of CLL cells in the peripheral blood. 23 It has been observed that AID mRNA is preferentially expressed in CLL cases with unmutated VH genes. 24 AID is an essential component of the canonical somatic hypermutation process in healthy B cells and its expression in CLL is potentially relevant to the disease. Interestingly, a subsequent study showed AID mRNA to be expressed only in a very small fraction of the CLL clone, this fraction varying from patient to patient and from time to time. 25 Accordingly, the present analysis of AID protein expression revealed very low but detectable levels in EHEB as well as in the CLL subgroups with slight differences in expression levels among the patient samples, which were independent of the VH mutation status and the karyotype (Figure 1h ). Moreover, the expression level of AID in CD19 þ -Bcells was very similar to that of CLL cases (Figure 2d) . Thus, AID protein expression detected by immunoblotting does not seem to be a surrogate marker for the VH mutation status in CLL.
Smac/DIABLO was easily detectable in CLL samples with an expression level as high as in EHEB regardless of the CLL subgroup affiliation defined by the karyotype and the VH mutation status (Figure 1f) . Despite the presence of XIAP in CLL cells and its upregulation in conditions where apoptosis is prevented, no caspase-inhibiting effect of IAP has been detected. 26 This phenomenon might be partly explained by the uniformly strong expression of Smac/DIABLO in CLL cells, confirmed in the present study, possibly sufficient to overcome the caspase-inhibiting effect of IAPs. 26 This hypothesis is supported by the fact that the expression of Smac/DIABLO was lower in CD19 þ -B-cells as compared to CLL (Figure 2f ).
Taken together, characteristic protein expression patterns were observed when comparing lymphoma cell lines and CLL samples, but none of the chromosome 12 candidate gene products investigated appeared to be consistently deregulated as a result of trisomy 12 or the VH mutation status in CLL. Additional cytogenetic aberrations such as 17p deletion, 11q deletion or 13q deletion did not have any impact on the expression of the analyzed proteins. Hence, the significantly longer TFS time of the VH-mutated vs the VH-unmutated group cannot be explained by a differential expression of the investigated proteins.
Interestingly, recent microarray and quantitative PCR studies 9, 10 revealed an upregulation of the RNA levels of genes located on chromosome 12 (such as p27 and CDK4) in CLL cases with trisomy 12. In the CLL subgroup with trisomy 12, 17 of the top 25 deregulated genes were localized on chromosome 12 and all were upregulated, indicating a gene dosage effect as potential pathomechanism. 9 However, this upregulation of genes located on chromosome 12 on the RNA level was not observed in the current study on the protein level despite a high tumor load of the samples investigated. This may be due to additional post-transcriptional mechanisms of deregulation or due to a lower sensitivity of immunoblotting to detect subtle expression differences. The upregulations observed on the RNA level were 1.36-fold for CDK4 and 1.32-fold for p27, 10 differences that may well be beyond the limits of quantitation of immunoblotting.
The analysis of CD19 þ -B-cells from healthy donors in comparison to CLL cases revealed higher protein expression levels in CLL for CDK4, p27, Smac/DIABLO and STAT6. Whether these proteins qualify as candidates for targeted therapies of CLL has to be further evaluated, especially with regard to genetic high-risk subgroups of CLL (patients with 17p deletion/p53 mutation and 11q deletion, respectively).
